To Assess Signs and Symptoms in Women Affected by GSM After One Cycle of Pixel CO2-Alma Fractionated Laser

Dr. Filippo Murina

Status

Unknown

Conditions

Dyspareunia

Vaginal Dryness

Burning

Pain

Dysuria

Genitourinary Syndrome of Menopause (GSM)

Treatments

Device: Fractionated Laser (Pixel CO.2-Alma)

Device: Fractionated Laser (Pixel CO2-Alma)

Study type

Interventional

Funder types

Other

Identifiers

NCT05156502

SSSM-2020-03.1

Details and patient eligibility

About

Genitourinary syndrome of menopause (GSM) occurs in approximately 50% of menopausal women but is both underrecognized and undertreated despite numerous treatment options. Vaginal dryness, irritation, dyspareunia, urinary frequency, and urinary urgency are some of the more common symptoms that can have a negative effect on women's lives and relationships. In particular, dyspareunia is localized in the vestibule with specific trophic changes more evident than those localized in vagina. The CO2 fractionated laser, has also been found to be useful in several studies for the treatment of vaginal atrophy.

In this open comparative study, 70 female menopausal subjects aged between 40 and 70 years old at inclusion, having symptoms of GSM (Vaginal dryness, burning/pain, dyspareunia,dysuria), have given her informed consent and meet all the eligibility criteria, will be enrolled. The two groups of comparison will be 35 subjects treated into vagina and vestibule, versus 35 subjects treated into vagina, only. Subjects will come to a total of 6 visits over a period of 3 months.

The primary objective of the study is to evaluate the performance and safety of Pixel CO2-Alma Fractionated Laser comparing its administration into vagina and vestibule versus into vagina, only. The evaluated outcomes are vaginal dryness, burning/pain, dyspareunia, sensitivity to touch at Swab test, Female Sexual Function Index (FSFI) and Vulval Pain Functional Questionnaire (VQ) at day 84 and 120 and the safety during all the study. The secondary objectives are the evaluation of vaginal and vestibular trophism, measured by Vaginal Health Index (VHI) and Vestibular Health Score (VHS) at the FU visits.

Enrollment

70 estimated patients

Sex

Female

Ages

40 to 70 years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

menopausal women aged between 40 and 70 years old (defined as Absence of menstruation for 12 consecutive months).
women affected by Genitourinary syndrome of menopause (GSM) with Vaginal dryness, burning/pain, dyspareunia, dysuria.
women not treated with Replacement therapy with estrogen and progestogen (HT) or estrogen alone (ET) or selective estrogen receptor modulators (SERMS) in the last 3 months

Exclusion criteria

hypersensitivity to laser
clinically significant findings on physical examination
any chronic medical condition or psychologic disorder that per opinion of the Principal Investigator would make the patient ineligible for the study
vulvo-vestibular lesion not related with GSM
active vaginal or vulvar infections (e.g., herpes, candida, STIs)
prolapse beyond the hymen
subject has a history of scarring alteration (ie, keloid formation)
unknown past or active history of vaginal bleeding disorders
any condition or behavior indicating to the Principal Investigator that the Subject is unlikely to be compliant with study procedures and visits